Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Elan moves before the LYONs roar

Elan Corp. plc is making moves designed to avoid a cash crunch when its LYONS come due 18 months from now. Given the state of both ELN and the equity markets, it's not too soon to plan.

ELN shares have fallen 96% this year, wiping $14.4 billion off its valuation, which is now $702.5

Read the full 537 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers